Coeptis Therapeutics Announces Board and Compensation Changes
Ticker: COEPW · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1759186
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Coeptis Therapeutics is changing its board and executive pay structure.
AI Summary
On March 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in board composition and executive compensation can signal strategic shifts or governance adjustments within the company, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's future direction and financial strategy.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- Bull Horn Holdings Corp. (company) — Former Company Name
- March 21, 2025 (date) — Date of Earliest Event Reported
- March 27, 2025 (date) — Filing Date
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors and election of new directors, but the specific names and number of individuals are not detailed in the provided text.
What are the details of the new compensatory arrangements for officers?
The filing mentions compensatory arrangements of certain officers, but the specific details of these arrangements are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 21, 2025.
What was Coeptis Therapeutics Holdings, Inc. formerly known as?
The company was formerly known as Bull Horn Holdings Corp.
In which state was Coeptis Therapeutics Holdings, Inc. incorporated?
The company was incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Coeptis Therapeutics Holdings, Inc. (COEPW).